* * * * * * * * * Welcome to STN International NEWS 1 Web Page for STN Seminar Schedule - N. America NEWS 2 OCT 02 CA/CAplus enhanced with pre-1907 records from Chemisches Zentralblatt NEWS 3 OCT 19 BEILSTEIN updated with new compounds NEWS 4 NOV 15 Derwent Indian patent publication number format enhanced NEWS 5 NOV 19 WPIX enhanced with XML display format NEWS 6 NOV 30 ICSD reloaded with enhancements NEWS 7 DEC 04 LINPADOCDB now available on STN NEWS 8 DEC 14 BEILSTEIN pricing structure to change NEWS 9 DEC 17 USPATOLD added to additional database clusters NEWS 10 DEC 17 IMSDRUGCONF removed from database clusters and STN NEWS 11 DEC 17 DGENE now includes more than 10 million sequences NEWS 12 DEC 17 TOXCENTER enhanced with 2008 MeSH vocabulary in MEDLINE segment NEWS 13 DEC 17 MEDLINE and LMEDLINE updated with 2008 MeSH vocabulary NEWS 14 DEC 17 CA/CAplus enhanced with new custom IPC display formats NEWS 15 DEC 17 STN Viewer enhanced with full-text patent content from USPATOLD NEWS 16 JAN 02 STN pricing information for 2008 now available NEWS 17 JAN 16 CAS patent coverage enhanced to include exemplified prophetic substances NEWS 18 JAN 28 USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats NEWS 19 JAN 28 MARPAT searching enhanced NEWS 20 JAN 28 USGENE now provides USPTO sequence data within 3 days of publication NEWS 21 JAN 28 TOXCENTER enhanced with reloaded MEDLINE segment NEWS 22 JAN 28 MEDLINE and LMEDLINE reloaded with enhancements NEWS 23 FEB 08 STN Express, Version 8.3, now available NEWS 24 FEB 20 PCI now available as a replacement to DPCI NEWS 25 FEB 25 IFIREF reloaded with enhancements NEWS 26 FEB 25 IMSPRODUCT reloaded with enhancements NEWS 27 FEB 29 WPINDEX/WPIDS/WPIX enhanced with ECLA and current U.S. National Patent Classification NEWS EXPRESS FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3,

AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008

NEWS HOURS STN Operating Hours Plus Help Desk Availability Welcome Banner and News Items NEWS LOGIN NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 13:57:13 ON 11 MAR 2008

=> file caplus COST IN U.S. DOLLARS

SINCE FILE TOTAL
ENTRY SESSION
0.21 0.21

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 13:57:56 ON 11 MAR 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 11 Mar 2008 VOL 148 ISS 11 FILE LAST UPDATED: 10 Mar 2008 (20080310/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

=> s direct (5a) compress? (5a) tablet

667220 DIRECT

9027 DIRECTS

675195 DIRECT

(DIRECT OR DIRECTS)

319979 COMPRESS?

54878 TABLET

82646 TABLETS

97245 TABLET

(TABLET OR TABLETS)

L1 1076 DIRECT (5A) COMPRESS? (5A) TABLET

=> s 11 and ad<20001229

3926960 AD<20001229

(AD<20001229)

L2 112 L1 AND AD<20001229

=> s 12 and dextrose monohydrate

19155 DEXTROSE

11 DEXTROSES

19160 DEXTROSE

(DEXTROSE OR DEXTROSES)

28917 MONOHYDRATE

837 MONOHYDRATES

```
29433 MONOHYDRATE
                (MONOHYDRATE OR MONOHYDRATES)
          160 DEXTROSE MONOHYDRATE
                (DEXTROSE (W) MONOHYDRATE)
L3
            0 L2 AND DEXTROSE MONOHYDRATE
=> s 12 and dextrose
        19155 DEXTROSE
          11 DEXTROSES
        19160 DEXTROSE
               (DEXTROSE OR DEXTROSES)
            4 L2 AND DEXTROSE
L4
=> d 14 ibib kwic 1-
YOU HAVE REQUESTED DATA FROM 4 ANSWERS - CONTINUE? Y/(N):y
    ANSWER 1 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2001:185548 CAPLUS <<LOGINID::20080311>>
DOCUMENT NUMBER:
                       134:227386
TITLE:
                       Sugar compositions for tableting containing amorphous
                       particulate trehalose
INVENTOR(S):
                       James, Martin John; Heath, Christopher; Sistern, Hugh
                       Richard
                       British Sugar PLC, UK
PATENT ASSIGNEE(S):
SOURCE:
                       PCT Int. Appl., 16 pp.
                       CODEN: PIXXD2
                       Patent
DOCUMENT TYPE:
LANGUAGE:
                       English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:
    PATENT NO.
                     KIND DATE
                                        APPLICATION NO.
                                                              DATE
                                         _____
                      ----
    WO 2001017503 A2 20010315 WO 2000-GB3436 WO 2001017503 A3 20010920
                                                               20000907 <--
        W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
            CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
            HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
            LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
            SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
            YU, ZA, ZW
        RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
            DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
            CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
                       A 20010314 GB 1999-21335
GB 1999-21335
                                                               19990909 <--
    GB 2353933
                              GB 1999-21335 A 19990909
DATE APPLICATION NO. DATE
PRIORITY APPLN. INFO.:
    PATENT NO. KIND
    _____
                       ____
                              _____
                                         ______
    WO 2001017503 A2 20010315
WO 2001017503 A3 20010920
                                        WO 2000-GB3436 20000907 <--
                              20010315
PΙ
```

AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,

```
YU, ZA, ZW
        RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
            DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
            CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
    GB 2353933
                     A 20010314 GB 1999-21335
                                                               19990909 <--
    . . . major fraction of powdered sucrose. Preferably, the amorphous
AB
    trehalose is a spray dried. Also provided are methods of manufacturing a
    tablet by direct compression of the compns.,
    and tablets obtainable thereby.
    50-99-7, Dextrose, biological studies 57-48-7, Fructose,
    biological studies 57-50-1, Sucrose, biological studies 63-42-3,
    Lactose 69-79-4, Maltose 99-20-7, Trehalose 6138-23-4, Trehalose
    dihydrate
    RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
       (sugar compns. for tableting containing amorphous particulate trehalose)
    ANSWER 2 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:
                      1998:776656 CAPLUS <<LOGINID::20080311>>
DOCUMENT NUMBER:
                       130:29239
TITLE:
                       Fast-dissolving tablets and methods of their
                       manufacture by direct compression
INVENTOR(S):
                       Eoga, Anthony B. J.; Valia, Kirti H.
PATENT ASSIGNEE(S):
                       Warner-Lambert Co., USA
                       PCT Int. Appl., 34 pp.
SOURCE:
                       CODEN: PIXXD2
DOCUMENT TYPE:
                       Patent
                       English
LANGUAGE:
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:
                                        APPLICATION NO.
                                                             DATE
    PATENT NO.
                      KIND DATE
                              _____
                      ____
                       A1 19981126 WO 1998-US8821
    WO 9852541
                                                              19980504 <--
        W: AL, AU, BA, BB, BG, BR, CA, CN, CZ, EE, GE, GW, HU, ID, IL, IS,
            JP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG,
            SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD,
            RU, TJ, TM
        RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,
            FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,
            CM, GA, GN, ML, MR, NE, SN, TD, TG
    US 5939091
                       A
                           19990817
                                       US 1998-40749
                                                               19980318 <--
    AU 9871726
                        A
                              19981211
                                         AU 1998-71726
                                                              19980504 <--
    ZA 9804229
                             19991119
                                         ZA 1998-4229
                       Α
                                                               19980519 <--
                                                           P 19970520
PRIORITY APPLN. INFO.:
                                         US 1997-47217P
                                                         W 19980504
                                         WO 1998-US8821
                       4
                             THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
REFERENCE COUNT:
                             RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT
                      KIND DATE APPLICATION NO. DATE
    PATENT NO.
    _____
                       ____
                              _____
                                         ______
    WO 9852541 A1 19981126
                                       WO 1998-US8821 19980504 <--
PΙ
        W: AL, AU, BA, BB, BG, BR, CA, CN, CZ, EE, GE, GW, HU, ID, IL, IS, JP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG,
            SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD,
            RU, TJ, TM
        RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,
            FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,
```

```
CM, GA, GN, ML, MR, NE, SN, TD, TG
    US 5939091 A 19990817 US 1998-40749 19980318 <--
AU 9871726 A 19981211 AU 1998-71726 19980504 <--
ZA 9804229 A 19991119 ZA 1998-4229 19980519 <--
    pharmaceutical tablet direct compression
    density; alk earth metal salt pharmaceutical tablet
    50-70-4, Sorbitol, biological studies 50-99-7, Dextrose,
    biological studies 57-50-1, Sucrose, biological studies 69-65-8,
    Mannitol 69-79-4, Maltose 87-99-0, Xylitol 471-34-1, Calcium
    carbonate, biological studies 546-93-0, Magnesium carbonate 585-88-6,
    Maltitol 1305-62-0, Calcium hydroxide, biological studies 1309-42-8,
    Magnesiumhydroxide 1343-88-0, Magnesium silicate 11137-98-7, Magnesium
    aluminate 21645-51-2, Aluminum hydroxide, biological studies
    39366-43-3, Aluminum magnesiumhydroxide
    RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
       (fast-dissolving tablets and methods of their manufacture by direct
       compression)
    ANSWER 3 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1987:561691 CAPLUS <<LOGINID::20080311>>
DOCUMENT NUMBER:
                       107:161691
                   Improvements in and relating to effervescent
TITLE:
                      acetylsalicylic acid tablets
INVENTOR(S):

Jones, Stephen Keith; Wilson, Peter David
PATENT ASSIGNEE(S):

Nicholas Pty. Ltd., Australia
SOURCE:
                      Eur. Pat. Appl., 26 pp.
                       CODEN: EPXXDW
DOCUMENT TYPE:
                      Patent
                       English
LANGUAGE:
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:
    ED 219227
                                        APPLICATION NO.
                                                              DATE
                      EP 219337 A2 19870422 EP 1986-307908 EP 219337 A3 19870916
                                                              19861013 <--
       R: AT, BE, CH, DE, ES, FR, GR, IT, LI, LU, NL, SE
    GB 2189700 A 19871104
GB 2189700 B 19891018
                                        GB 1986-24520
                                                               19861013 <--
    GB 2189700 B 19891018
WO 8702242 A1 19870423 WO 1986-AU304
                                                               19861014 <--
    W: AU, DK, FI, JP, KR, NO, US
PRIORITY APPLN. INFO.:
```

```
EP 219337
                  A2
РΤ
                              19870422 EP 1986-307908
                                                                19861013 <--
                             19870916
    EP 219337
                       А3
        R: AT, BE, CH, DE, ES, FR, GR, IT, LI, LU, NL, SE
    GB 2189700 A 19871104
                                         GB 1986-24520
                                                                19861013 <--
    GB 2189700
                       В
                              19891018
                                        WO 1986-AU304
    WO 8702242
                       A1
                             19870423
                                                                19861014 <--
        W: AU, DK, FI, JP, KR, NO, US
    AU 8665290
                A
                            19870505
                                        AU 1986-65290
                                                                19861014 <--
    AU 600687
                       В2
                             19900823
    JP 63501505
                       Τ
                            19880609
                                        JP 1986-505526
                                                               19861014 <--
    JP 07008797
                       В
                             19950201
    CA 1275252
                      С
                             19901016 CA 1986-520413
                                                               19861014 <--
                      A
                            19870624 ZA 1986-7816
    ZA 8607816
                                                               19861015 <--
                       A
                             19870610 NO 1987-2425
    NO 8702425
                                                               19870610 <--
    DK 8703020
                       A
                             19870612 DK 1987-3020
                                                               19870612 <--
                           19870612 FI 1987-2638
19910806 US 1990-491739
    FI 8702638
                       Α
                                                               19870612 <--
    US 5037657
                       Α
                                                               19900312 <--
    Dextrose and/or sucrose are used as disintegrants or dissoln.
AB
    aids in effervescent tablets of acetylsalicylic acid (I), which are formed
    by direct compression. An effervescent I tablet was produced by
    direct compression of the dry powder mixture containing coated
    I 350, NaHCO3 439, Na2CO3 24, citric acid 240, and spray-crystallized
    dextrose 400 mg. Control tablets contained no dextrose.
    The inclusion of dextrose gave faster dissoln. times both
    initially and after 12 wk storage at 20° or 40°, at hardness
    ranges of 4-6. . .
ST
    aspirin tablet effervescent sucrose dextrose; acetylsalicylate
    tablet effervescent sucrose dextrose; disintegrator sucrose
    dextrose aspirin effervescent tablet
    Pharmaceutical dosage forms
ΙT
       (tablets, effervescent, of aspirin, dextrose or sucrose in,
       as disintegrator)
    50-99-7, Dextrose, biological studies 57-50-1, biological
ΙT
    studies
    RL: BIOL (Biological study)
       (effervescent aspirin tablets containing spray crystallized, as
disintegrator)
    50-78-2, Acetylsalicylic acid
    RL: PROC (Process)
       (effervescent tablet formulation of, dextrose in, as
       disintegrator)
    ANSWER 4 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:
                   1972:61236 CAPLUS <<LOGINID::20080311>>
DOCUMENT NUMBER:
                       76:61236
ORIGINAL REFERENCE NO.: 76:9877a,9880a
                       Compressed tablets containing dextrose
TITLE:
                       Brouillard, Robert E.; Griffith, Charles L.
INVENTOR(S):
PATENT ASSIGNEE(S):
                       Penick and Ford, Ltd., Inc.
SOURCE:
                       U.S., 6 pp.
                       CODEN: USXXAM
DOCUMENT TYPE:
                       Patent
                       English
LANGUAGE:
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:
```

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
	US 3619292	 A	19711109	US 1968-744645		19680715 <
	DK 125824	В	19730514	DK 1969-3481		19690627 <
	FR 2012974	A5	19700327	FR 1969-23744		19690711 <
	ES 369431	A1	19710601	ES 1969-369431		19690711 <
	CA 943064	A1	19740305	CA 1969-56801		19690711 <
	CH 521720	A	19720430	СН 1969-521720		19690714 <
	GB 1275086	A	19720524	GB 1969-1275086		19690714 <
	BE 736100	A	19691216	BE 1969-736100		19690715 <
	NL 6910896	A	19700119	NL 1969-10896		19690715 <
	DE 1935891	A	19700122	DE 1969-1935891		19690715 <
	DE 1935891	В2	19730510			
	DE 1935891	C3	19731213			
PRI	ORITY APPLN. IN	FO.:		US 1968-744645	A	19680715
ΤΙ	Compressed tal	blets contain	ing dextros	se		
	PATENT NO.	KIND	DATE 	APPLICATION NO.		DATE
ΡI	US 3619292		19711109			19680715 <
	DK 125824	В		DK 1969-3481		19690627 <
	FR 2012974	A5	19700327	FR 1969-23744		19690711 <
	ES 369431	A1	19710601	ES 1969-369431		19690711 <
	CA 943064	A1	19740305	CA 1969-56801		19690711 <
	CH 521720	A	19720430	CH 1969-521720		19690714 <
	GB 1275086	A	19720524	GB 1969-1275086		19690714 <
	BE 736100	A	19691216	BE 1969-736100		19690715 <
	NL 6910896	A	19700119	NL 1969-10896		19690715 <
	DE 1935891	А	19700122	DE 1969-1935891		19690715 <
	DE 1935891	В2	19730510			
	DE 1935891	C3	19731213			
AB	Massecuite ago	gregated tota	ıl sugar(MAI	S) granules are used	as	a binder or
	binder-filler	in manufactu	ring compre	essed tablets,		
	preferably by	direct compr	ession of a	a particulate		
	tableting comp	position in w	hich the MA	ATS granules have bee	n bl	ended. The MATS
				nt carrier, and/or as		
				ranules of high dext		
	[50-99-7] 000	irralant (>02%	·) compriso	anhorical aggregates	o.f	cohorod

S [50-99-7] equivalent (>92%) comprise spherical aggregates of cohered microcrystals of dextrose internally containing the residual oligosaccharides of the starch hydrolysis in solid solution, the granules being free-flowing, nonhygroscopic, porous, and compressible. Thus spray-dried, aggregated, microcryst. total corn sugar (92-3% dextrose) was blended with 0.1 weight % Mg stearate powder, which was added as a lubricant to prevent adhering to the. . ST dextrose tableting compn; sugar tableting compn

=> s chewable (5a) tablet 1658 CHEWABLE

11 CHEWABLES

1660 CHEWABLE

(CHEWABLE OR CHEWABLES)

54878 TABLET

82646 TABLETS

97245 TABLET

(TABLET OR TABLETS)

L5 1312 CHEWABLE (5A) TABLET => s chewable (5a) tablet and desxtrose

1658 CHEWABLE

```
11 CHEWABLES
          1660 CHEWABLE
                (CHEWABLE OR CHEWABLES)
         54878 TABLET
         82646 TABLETS
         97245 TABLET
                (TABLET OR TABLETS)
          1312 CHEWABLE (5A) TABLET
            0 DESXTROSE
             O CHEWABLE (5A) TABLET AND DESXTROSE
L6
=> s chewable (5a) tablet and dextrose
          1658 CHEWABLE
           11 CHEWABLES
          1660 CHEWABLE
                (CHEWABLE OR CHEWABLES)
         54878 TABLET
         82646 TABLETS
         97245 TABLET
                (TABLET OR TABLETS)
         1312 CHEWABLE (5A) TABLET
         19155 DEXTROSE
            11 DEXTROSES
         19160 DEXTROSE
                (DEXTROSE OR DEXTROSES)
L7
            53 CHEWABLE (5A) TABLET AND DEXTROSE
=> s chewable (5a) tablet and dextrose and direct (3a) compression
          1658 CHEWABLE
           11 CHEWABLES
          1660 CHEWABLE
                 (CHEWABLE OR CHEWABLES)
         54878 TABLET
         82646 TABLETS
         97245 TABLET
                 (TABLET OR TABLETS)
         1312 CHEWABLE (5A) TABLET
         19155 DEXTROSE
           11 DEXTROSES
         19160 DEXTROSE
                 (DEXTROSE OR DEXTROSES)
        667220 DIRECT
          9027 DIRECTS
        675195 DIRECT
                 (DIRECT OR DIRECTS)
        132237 COMPRESSION
          1404 COMPRESSIONS
        132907 COMPRESSION
                 (COMPRESSION OR COMPRESSIONS)
          2246 DIRECT (3A) COMPRESSION
L8
             2 CHEWABLE (5A) TABLET AND DEXTROSE AND DIRECT (3A) COMPRESSION
=> s chewable (5a) tablet and dextrose and direct (3a) compression and ad<20001229
```

1658 CHEWABLE 11 CHEWABLES 1660 CHEWABLE

```
(CHEWABLE OR CHEWABLES)
        54878 TABLET
        82646 TABLETS
        97245 TABLET
               (TABLET OR TABLETS)
         1312 CHEWABLE (5A) TABLET
        19155 DEXTROSE
          11 DEXTROSES
        19160 DEXTROSE
               (DEXTROSE OR DEXTROSES)
       667220 DIRECT
         9027 DIRECTS
       675195 DIRECT
               (DIRECT OR DIRECTS)
       132237 COMPRESSION
         1404 COMPRESSIONS
       132907 COMPRESSION
               (COMPRESSION OR COMPRESSIONS)
         2246 DIRECT (3A) COMPRESSION
      3926960 AD<20001229
               (AD<20001229)
L9
            1 CHEWABLE (5A) TABLET AND DEXTROSE AND DIRECT (3A) COMPRESSION
              AND AD<20001229
=> d 19
   ANSWER 1 OF 1 CAPLUS COPYRIGHT 2008 ACS on STN
L9
AN 1970:103755 CAPLUS <<LOGINID::20080311>>
   72:103755
DN
OREF 72:18837a,18840a
TI Tablets
IN Brouillard, Robert E.; Griffith, Charles L.
PA Penick and Ford, Ltd., Inc.
SO Ger. Offen., 27 pp.
    CODEN: GWXXBX
DT
   Patent
LA
    German
FAN.CNT 2
                  KIND DATE APPLICATION NO. DATE
    PATENT NO.
                       ____
                             _____
                                         _____
    DE 1935891
                       A
                             19700122
                                        DE 1969-1935891
PΤ
                                                              19690715 <--
    DE 1935891
                       В2
                             19730510
    DE 1935891
                      C3
                             19731213
US 3619292 A 19711109 US 1968-744645 19680715 <--
PRAI US 1968-744645 A 19680715
=> d his full
    (FILE 'HOME' ENTERED AT 13:57:13 ON 11 MAR 2008)
    FILE 'CAPLUS' ENTERED AT 13:57:56 ON 11 MAR 2008
          1076 SEA ABB=ON PLU=ON DIRECT (5A) COMPRESS? (5A) TABLET
L1
```

L2	112	SEA ABB=ON	PLU=ON	L1 AND AD	<2000	1229			
L3	0	SEA ABB=ON	PLU=ON	L2 AND DE	XTROSI	HONOM	YDRA:	ΓE	
L4	4	SEA ABB=ON	PLU=ON	L2 AND DE	XTROSI	₹.			
		D L4 IBIB K	WIC 1-						
L5	1312	SEA ABB=ON	PLU=ON	CHEWABLE	(5A)	TABLET			
L6	0	SEA ABB=ON	PLU=ON	CHEWABLE	(5A)	TABLET	AND	DESXTROSI	己
L7	53	SEA ABB=ON	PLU=ON	CHEWABLE	(5A)	TABLET	AND	DEXTROSE	
L8	2	SEA ABB=ON	PLU=ON	CHEWABLE	(5A)	TABLET	AND	DEXTROSE	AND
		DIRECT (3A)	COMPRES	SION					
L9	1	SEA ABB=ON	PLU=ON	CHEWABLE	(5A)	TABLET	AND	DEXTROSE	AND
		DIRECT (3A)	COMPRES	SION AND A	D<2000	01229			
		D L9							

FILE HOME

FILE CAPLUS

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 11 Mar 2008 VOL 148 ISS 11 FILE LAST UPDATED: 10 Mar 2008 (20080310/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

=> s 14 and sucralose 1235 SUCRALOSE

L10 0 L4 AND SUCRALOSE

=> s 14 and saccharin

11692 SACCHARIN 105 SACCHARINS 11715 SACCHARIN

(SACCHARIN OR SACCHARINS)

L11 0 L4 AND SACCHARIN

=> s (12 or 17) and sucralose 1235 SUCRALOSE

L12 14 (L2 OR L7) AND SUCRALOSE

=> d 112 ibib kwic 1-

YOU HAVE REQUESTED DATA FROM 14 ANSWERS - CONTINUE? Y/(N):y

L12 ANSWER 1 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN ACCESSION NUMBER: 2007:1092492 CAPLUS <<LOGINID::20080311>>

DOCUMENT NUMBER: 147:392459

TITLE: Taste masked pharmaceutical composition comprising

water insol. polymer for oral solid dosage form and

process for preparing the same

INVENTOR(S): Kashid, Namdev; Chouhan, Pradeep; Mukherji, Gour

PATENT ASSIGNEE(S): Jubilant Organosys Limited, India

SOURCE: PCT Int. Appl., 27pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PA	PATENT NO.						KIND DATE			APPL	ICAT	ION I	DATE					
WC	WO 2007108010					_	20070927		WO 2007-IN109					20070319				
	W:	ΑE,	AG,	AL,	AM,	ΑT,	ΑU,	AZ,	BA,	BB,	BG,	BH,	BR,	BW,	BY,	BZ,	CA,	
		CH,	CN,	CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	EG,	ES,	FΙ,	GB,	
		GD,	GE,	GH,	GM,	GT,	HN,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	ΚE,	KG,	KM,	
		KN,	KP,	KR,	KΖ,	LA,	LC,	LK,	LR,	LS,	LT,	LU,	LY,	MA,	MD,	MG,	MK,	
		MN,	MW,	MX,	MY,	ΜZ,	NA,	NG,	ΝI,	NO,	NZ,	OM,	PG,	PH,	PL,	PT,	RO,	
		RS,	RU,	SC,	SD,	SE,	SG,	SK,	SL,	SM,	SV,	SY,	ΤJ,	TM,	TN,	TR,	TT,	
		TZ,	UA,	UG,	US,	UZ,	VC,	VN,	ZA,	ZM,	ZW							
	RW:	AT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,	EE,	ES,	FΙ,	FR,	GB,	GR,	HU,	ΙE,	
		IS,	IT,	LT,	LU,	LV,	MC,	MT,	NL,	PL,	PT,	RO,	SE,	SI,	SK,	TR,	BF,	
		ВJ,	CF,	CG,	CI,	CM,	GA,	GN,	GQ,	GW,	ML,	MR,	ΝE,	SN,	TD,	ΤG,	BW,	
		GH,	GM,	ΚE,	LS,	MW,	MZ,	NA,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AM,	ΑZ,	
		BY,	KG,	KΖ,	MD,	RU,	ТJ,	TM										
IN	1 2006	DE00	752		A		2007	0928		IN 2	006-	DE 75	2		2	0060	321	
PRIORIT	RIORITY APPLN. INFO.:									IN 2006-DE752					A 20060321			
T	1 7			7 1														

IT Chewable drug delivery systems

Pharmaceutical tablets

(chewable tablets; taste masked pharmaceutical

composition comprising water insol. polymer for oral solid dosage form and process for preparing same)

50-70-4, Sorbitol, biological studies 50-99-7, Dextrose, ΙT biological studies 57-11-4, Stearic acid, biological studies 57-50-1, Sucrose, biological studies 63-42-3, Lactose 69-65-8, Mannitol 79-41-4D, Methacrylic acid, copolymer 87-99-0, Xylitol 144-55-8, Sodium bicarbonate, biological studies 151-21-3, Sodium lauryl sulfate, biological studies 497-19-8, Sodium carbonate, biological studies 546-93-0, Magnesium carbonate 557-04-0, Magnesium stearate 585-88-6, Maltitol 1327-43-1, Magnabrite F 1338-39-2, Sorbitan monolaurate 1338-41-6, Sorbitan monostearate 1592-23-0, Calcium stearate 4070-80-8, Sodium stearyl fumarate 7631-86-9, Silica, biological studies 7647-14-5, Sodium chloride, biological studies 7757-93-9, Dibasic calcium phosphate 7758-87-4, Tribasic calcium phosphate 7778-18-9, Calcium sulfate 9000-30-0, Guar gum 9000-65-1, Tragacanth 9000-69-5, 9003-39-8, Polyvinylpyrrolidone 9002-89-5, Polyvinyl alcohol 9004-32-4, Carboxymethyl cellulose 9004-34-6, Cellulose, biological studies 9004-38-0, Cellulose acetate phthalate 9004-53-9, Dextrin 9004-57-3, Ethyl cellulose 9004-62-0, Hydroxyethyl cellulose 9004-65-3, Hydroxypropyl methylcellulose 9004-67-5, Methylcellulose 9005-25-8, Starch, biological studies 9005-38-3, Sodium alginate 9005-65-6, Polysorbate 80 9049-76-7, Hydroxypropyl starch 9050-04-8, Calcium carboxymethylcellulose 9050-31-1, Hydroxypropylmethyl cellulose

phthalate 14807-96-6, Talc, biological studies 14987-04-3, Magnesium trisilicate 22839-47-0, Aspartame 24938-16-7, Eudragit EPO 25322-68-3, Polyethylene glycol 26266-57-9, Sorbitan monopalmitate 31566-31-1, Glyceryl monostearate 34552-83-5, Loperamide hydrochloride 52907-01-4, Cellulose acetate trimellitate 53179-11-6, Loperamide 53237-50-6 55589-62-3, Acesulfame potassium 56038-13-2, Sucralose 71138-97-1, Hydroxypropylmethyl cellulose acetate succinate 79794-75-5, Loratidine 83799-24-0, Fexofenadine 84057-84-1, Lamotrigine 99614-02-5, Ondansetron 100643-71-8, 103628-46-2, Sumatriptan 106266-06-2, Risperidone Desloratadine 106392-12-5, Polyoxyethylenepolyoxypropylene block copolymer 109889-09-0, Granisetron 121679-13-8, Naratriptan 132539-06-1, Olanzapine 158966-92-8, Montelukast 434943-29-0, Pearlitol 300DC RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (taste masked pharmaceutical composition comprising water insol. polymer for oral solid dosage form and process for preparing same)

L12 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:873790 CAPLUS <<LOGINID::20080311>>

DOCUMENT NUMBER: 147:219439

TITLE: Calcium phosphate salts in dentifrice oral

compositions suitable as a tooth remineralizing agent

INVENTOR(S): Haas, Michael S.; Greenberg, Michael J.

Wm. Wrigley Jr. Company, USA PATENT ASSIGNEE(S): U.S. Pat. Appl. Publ., 16pp. SOURCE:

CODEN: USXXCO

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION: DATENT NO

	PATENT	KIND DATE				APPLICATION NO.						DATE					
					A1 20070809 A2 20070816												
		GE, KP, MN, RS, TZ,	CO, GH, KR, MW, RU, UA,	CR, GM, KZ, MX, SC, UG,	CU, GT, LA, MY, SD, US,	CZ, HN, LC, MZ, SE, UZ,	DE, HR, LK, NA, SG, VC,	DK, HU, LR, NG, SK, VN,	DM, ID, LS, NI, SL, ZA,	DZ, IL, LT, NO, SM, ZM,	EC, IN, LU, NZ, SV, ZW	EE, IS, LV, OM, SY,	EG, JP, LY, PG, TJ,	ES, KE, MA, PH, TM,	FI, KG, MD, PL, TN,	GB, KM, MG, PT, TR,	GD, KN, MK, RO, TT,
	RW:	CF, GM, KG,	IT, CG, KE, KZ,	LT, CI, LS, MD,	LU, CM, MW, RU,	LV, GA, MZ, TJ,	MC, GN, NA, TM	NL, GQ, SD,	PL, GW, SL,	PT, ML, SZ,	RO, MR, TZ,	SE, NE, UG,	SI, SN, ZM,	SK, TD, ZW,	TR, TG, AM,	BF, BW, AZ,	BJ, GH, BY,
PRIO	RITY APE																
AB	AB of the teeth, or in subsurface regions therein. Thus, chewing gum formulation comprised (in wt%): gum base 32.0, sucrose 55.4, sucralose 0.10, corn syrup 2.0, calcium carbonate 1.0, citric acid 2.5, fumaric acid 1.0, tricalcium phosphate 5.0, and orange flavor 1.0.																
IT	Chewabl Pharmac (che		cal	tabl	ets	-		hospl	hate	sal [.]	ts i:	n					

dentifrice oral compns. suitable as a tooth remineralizing agent) 50-21-5, Lactic acid, biological studies 50-70-4, Sorbitol, biological ΙT studies 50-81-7, Ascorbic acid, biological studies 50-99-7, Dextrose, biological studies 56-81-5, Glycerin, biological 56-84-8, Aspartic acid, biological studies 56-86-0, Glutamic acid, biological studies 57-11-4, Stearic acid, biological studies 57-50-1, Sucrose, biological studies 64-19-7, Acetic acid, biological studies 68-04-2, Sodium Citrate 77-92-9, Citric acid, biological studies 79-09-4, Propionic acid, biological studies 87-69-4, Tartaric acid, biological studies 87-99-0, Xylitol 89-78-1, Menthol 110-15-6, Succinic acid, biological studies 110-17-8, Fumaric acid, biological 124-04-9, Adipic acid, biological studies 138-86-3, Orange studies 471-34-1, Calcium Carbonate, biological studies 526-95-4, Flavor 557-04-0, Magnesium stearate 814-80-2, Calcium Lactate D-Gluconic acid 1306-06-5, Hydroxyapatite 6915-15-7, Malic acid 7722-88-5, Sodium Pyrophosphate 7757-93-9, Dicalcium phosphate 7758-23-8, Monocalcium phosphate 7758-87-4, Tricalcium phosphate 9005-32-7, Alginic acid 10103-46-5, Calcium phosphate 13767-12-9, Tetracalcium phosphate 14096-86-7 22839-47-0, Aspartame 24991-23-9 25513-46-6, Polyglutamic 25608-40-6, Polyaspartic acid 26063-13-8, Polyaspartic acid 50813-16-6, Sodium Metaphosphate 55589-62-3, Acesulfame potassium 56038-13-2, Sucralose RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(calcium phosphate salts in dentifrice oral compns. suitable as a tooth remineralizing agent)

L12 ANSWER 3 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:814044 CAPLUS <<LOGINID::20080311>>

DOCUMENT NUMBER: 147:173675

TITLE: Pharmaceutical compositions comprising a proton pump

inhibitor and protein component

INVENTOR(S): Phillips, Jeffrey O.

PATENT ASSIGNEE(S): The Curators of the University of Missouri, USA

SOURCE: PCT Int. Appl., 31pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT	KIN	D	DATE			APPLICATION NO.						DATE				
WO 2007							WO 2007-US60723					20070118				
WO 2007	0849	64		A3		20071227										
W:	ΑE,	ΑG,	AL,	ΑM,	ΑT,	ΑU,	ΑZ,	ΒA,	BB,	BG,	BR,	BW,	BY,	ΒZ,	CA,	CH,
	CN,	CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	EG,	ES,	FΙ,	GB,	GD,
	GE,	GH,	GM,	GT,	HN,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	ΚE,	KG,	KM,	KN,
	KP,	KR,	KΖ,	LA,	LC,	LK,	LR,	LS,	LT,	LU,	LV,	LY,	MA,	MD,	MG,	MK,
	MN,	MW,	MX,	MY,	MZ,	NA,	NG,	ΝI,	NO,	NZ,	OM,	PG,	PH,	PL,	PT,	RO,
	RS,	RU,	SC,	SD,	SE,	SG,	SK,	SL,	SM,	SV,	SY,	ТJ,	TM,	TN,	TR,	TT,
	TZ,	UA,	UG,	US,	UZ,	VC,	VN,	ZA,	ZM,	ZW						
RW:	ΑT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,	EE,	ES,	FΙ,	FR,	GB,	GR,	HU,	IE,
	IS,	ΙΤ,	LT,	LU,	LV,	MC,	NL,	PL,	PT,	RO,	SE,	SI,	SK,	TR,	BF,	ВJ,
	CF,	CG,	CI,	CM,	GΑ,	GN,	GQ,	GW,	ML,	MR,	NE,	SN,	TD,	ΤG,	BW,	GH,
	GM,	KΕ,	LS,	MW,	MZ,	NA,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AM,	AZ,	BY,

KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

US 2006-760256P P 20060119 PRIORITY APPLN. INFO.:

OTHER SOURCE(S): MARPAT 147:173675

. . to use of such compns. in treating and preventing diseases and/or disorders. Thus, a formulation contained hydrolyzed whey isolate 3000, sucralose 200, dextrose 200, aspartame 200, neotame 3, and pantoprazole 40 mg.

Chewable drug delivery systems

Pharmaceutical tablets

(chewable tablets; pharmaceutical compns.

comprising proton pump inhibitor and protein component)

L12 ANSWER 4 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:383101 CAPLUS <<LOGINID::20080311>>

146:365783 DOCUMENT NUMBER:

Oral compositions containing a salivation inducing TITLE:

agent

INVENTOR(S): Wynn, David W.; Robinson, Ronni

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 10pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent LANGUAGE: English

Pharmaceutical tablets

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

	PATENT NO.				KIND DATE			APPLICATION NO.						DATE				
	WO	2007	0413	67		A1 20070405 A2 20070412 A3 20071129				US 2005-239974 WO 2006-US38202								
		W: RW:	CN, GE, KR, MW, RU, UA, AT, IS, CF, GM,	CO, GH, KZ, MX, SC, UG, BE, IT, CG, KE,	CR, GM, LA, MY, SD, US, BG, LT, CI, LS,	CU, HN, LC, MZ, SE, UZ, CH, LU, CM, MW,	CZ, HR, LK, NA, SG, VC, CY, LV, GA, MZ,	AU, DE, HU, LR, NG, SK, VN, CZ, MC, GN,	DK, ID, LS, NI, SL, ZA, DE, NL, GQ, SD,	DM, IL, LT, NO, SM, ZM, DK, PL, GW, SL,	DZ, IN, LU, NZ, SV, ZW EE, PT, ML, SZ,	EC, IS, LV, OM, SY, ES, RO, MR, TZ,	EE, JP, LY, PG, TJ, FI, SE, NE,	EG, KE, MA, PH, TM, FR, SI, SN,	ES, KG, MD, PL, TN, GB, SK, TD,	FI, KM, MG, PT, TR, GR, TR,	GB, KN, MK, RO, TT, HU, BF, BW,	GD, KP, MN, RS, TZ, IE, BJ, GH,
	coated particles. The particles may be produced into a tablet form, such as a chewable tablet form, that provides for the immediate release of the active ingredient. Other oral dosage forms include thin film strips, gummis, foam tabs, and lozenges. Thus, chewable tablet was prepared containing sucralose powder 10 mg, dextrose monohydrate 956.3 mg, Polyplasdone XL-100 16.7 mg, magnesium stearate 8.0 mg, peppermint flavor 8.0 mg, and salivar												age hus,					
ST IT	inducing agent Succulene salivation stimulant chewable tablet Chewable drug delivery systems																	

(chewable tablets; oral compns. containing salivation-inducing agent)

57-50-1, Sucrose, biological studies 57-55-6, Propylene glycol, ΤТ 58-73-1, Diphenhydramine 77-92-9, Citric acid, biological studies biological studies 90-82-4, Pseudoephedrine 92-13-7, Pilocarpine 103-90-2, Acetaminophen 113-45-1, Methyl phenidate 125-71-3, Dextromethorphan 132-22-9, Chloropheniramine 471-34-1, Calcium carbonate, biological studies 523-87-5, Dimenhydrinate 532-32-1, Sodium benzoate 557-04-0, Magnesium stearate 569-65-3, Meclizine 5633-20-5, Oxybutynin 9000-07-1, Carrageenan 9003-39-8, Polyplasdone 9004-65-3, Hydroxypropylmethylcellulose 14807-96-6, Talc, biological studies 14838-15-4, Phenylpropanolamine 25322-68-3, Polyethylene glycol 25956-17-6, FD&C Red Number 40 34535-98-3D, Phenylcyclopropylamine, derivs. 51481-61-9, Cimetidine 53179-11-6, Loperamide 56038-13-2, Sucralose 66357-35-5, Ranitidine 68844-77-9, Astemizole 76824-35-6, Famotidine 77938-63-7, Dextrose monohydrate 79794-75-5, Loratadine 83799-24-0, Fexofenadine 83881-51-0, Cetirizine 100643-71-8, Desloratadine 107779-84-0D, analogs 930304-00-0, Succulence SN 061022 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (oral compns. containing salivation-inducing agent)

L12 ANSWER 5 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:544880 CAPLUS <<LOGINID::20080311>>

DOCUMENT NUMBER: 145:34230

TITLE: Medicament comprising fat-based confectionary coating

INVENTOR(S): Ream, Ronald L.; Matulewicz, Leonard; Wokas, William

J.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 15 pp., Cont.-in-part of U.S.

Ser. No. 44,113.

CODEN: USXXCO

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 22

PATENT INFORMATION:

PATENI	PATENT NO.				O	DATE		AP	PLI	ICATION	DATE			
	1856 5265 7746 AT, IE, 21105	BE, SI, 81	•	A1 A1 B1 A1 DE, LV, A1	FI	1998 2002 2003 ES, RO, 2002	FR,	CA US EP GB, G CY, A US	20 20 R, L,	005-2739 996-2431 000-5108 001-9535 IT, LI, TR 002-4411	.856 378 503 LU,	NL, SI	20051 19961 20000 20010 E, MC,	127 223 717 PT,
US 707 PRIORITY AF		INFO		B2		2006	0718	US US US CA WO	20 20 20 19 19	999-2868 000-5108 000-6313 002-4411 996-2271 999-US29 000-6715	378 326 .3 .889 .742 .552	A2 B2 A2 A3 A2	19990 20000 20000 20020 19961 19991 20000 20010	223 803 109 127 214 927

```
. . . 1b and water 215 lb. Coating was prepared containing acetaminophen
AΒ
     0.3490 g, peppermint flavor 0.0072 g, menthol flavor 0.0062 g,
     dextrose 1.4200 g, sucralose 0.0030 g, aspartame 0.0062
     and glucose 0.2080. The coating can be used to coat a consumable center.
ΙT
     Drug delivery systems
         (tablets, chewable; medicament comprising fat-based
        confectionary coating)
     50-70-4P, Sorbitol, biological studies 50-99-7P, Dextrose,
ΙT
     biological studies 56-81-5P, Glycerin, biological studies 77-92-9P,
     Citric acid, biological studies 90-80-2P, Glucono \delta-lactone
     103-90-2P, Acetaminophen 121-32-4P, Ethyl vanillin 121-33-5P, Vanillin
     471-34-1P, Calcium carbonate, biological studies 527-07-1P, Sodium
     gluconate 1405-86-3P 9005-25-8P, Starch, biological studies
     104859-78-1P, Sweetose 4300
     RL: IMF (Industrial manufacture); THU (Therapeutic use); BIOL (Biological
     study); PREP (Preparation); USES (Uses)
         (medicament comprising fat-based confectionary coating)
     81-07-2P, Saccharin 22839-47-0P, Aspartame 55589-62-3P, Acesulfame-k
     56038-13-2P, Sucralose
     RL: IMF (Industrial manufacture); THU (Therapeutic use); BIOL (Biological
     study); PREP (Preparation); USES (Uses)
         (sweetener; medicament comprising fat-based confectionary coating)
L12 ANSWER 6 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:76246 CAPLUS <<LOGINID::20080311>>
DOCUMENT NUMBER:
                           142:162634
TITLE:
                           Chewable tablets comprising
                          alginic acid and a carbonate precursor
INVENTOR(S):
                           Adusumilli, Prasad; Kim, Chungbin; Lech, Stanley J.;
                          Mehta, Naresh I.; Dinner, Dara L.
                        Smithkline Beecham Corporation, USA
PATENT ASSIGNEE(S):
SOURCE:
                          PCT Int. Appl., 81 pp.
                           CODEN: PIXXD2
DOCUMENT TYPE:
                          Patent
LANGUAGE:
                           English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:
                     KIND DATE APPLICATION NO. DATE
     PATENT NO.

      WO 2005007105
      A2
      20050127
      WO 2004-US22082
      20040709

      WO 2005007105
      A3
      20050519

          W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
              CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
              GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
              LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
              NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
         RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
                                 20050127 CA 2004-2531065 20040709
20050915 US 2004-888242 20040709
20060406 FP 2004-756833 20040709
     CA 2531065
                           A1
```

US 2005202084 A1 20050915 US 2004-888242 EP 1648411 A2 20060426 EP 2004-756833

```
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR
     US 2007178150
                          Α1
                                 20070802
                                             US 2006-583521
                                                                     20060109
     MX 2006PA00417
                          Α
                                 20060317
                                             MX 2006-PA417
                                                                     20060110
                                                                P 20030710
PRIORITY APPLN. INFO.:
                                             US 2003-486033P
                                             WO 2004-US22082
                                                                W 20040709
     Chewable tablets comprising alginic acid and a
     carbonate precursor
     A pharmaceutical composition in the form of a chewable tablet
AB
     for the suppression of gastric reflux comprising an alginic acid or salt
     thereof, a water-soluble carbonate radical precursor, a calcium. .
ST
     alginate carbonate precursor calcium salt antacid chewable
     tablet
     Antacids
ΤТ
     Flavoring materials
     Sweetening agents
        (chewable tablets comprising alginic acid,
        carbonate precursor and calcium salt)
ΤT
     Caseins, biological studies
     Gelatins, biological studies
     Hydrocarbon oils
     Polyoxyalkylenes, biological studies
     RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
        (chewable tablets comprising alginic acid,
        carbonate precursor and calcium salt)
ΙT
     Polyphosphoric acids
     RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
        (sodium salts; chewable tablets comprising alginic
        acid, carbonate precursor and calcium salt)
ΙT
     Drug delivery systems
        (tablets, chewable; chewable
        tablets comprising alginic acid, carbonate precursor and
        calcium salt)
ΤT
     9003-01-4D, crosslinked
     RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
        (Carbomer; chewable tablets comprising alginic
        acid, carbonate precursor and calcium salt)
ΙT
     50-70-4, Sorbitol, biological studies
                                              50-99-7, Dextrose,
     biological studies
                          57-48-7, Fructose, biological studies
     Sucrose, biological studies 63-42-3, Lactose 69-65-8, Mannitol
                       79-41-4D, Methacrylic acid, derivs., polymers
     69-79-4, Maltose
     81-07-2, Saccharin
                         87-99-0, Xylitol 144-55-8, Sodium bicarbonate,
     biological studies
                          298-14-6, Potassium bicarbonate 463-79-6D, Carbonic
     acid, alkali and alkaline earth metal salts 471-34-1, Calcium carbonate,
     biological studies 546-93-0, Magnesium carbonate 585-88-6, Maltitol
     814-80-2, Calcium lactate 1309-42-8, Magnesium hydroxide 1309-48-4,
     Magnesium oxide, biological studies
                                          1336-00-1 1592-23-0, Calcium
     stearate 7440-70-2D, Calcium, citrate maleate complexes
                                                                 7440-70-2D,
     Calcium, salts 7632-05-5, Sodium phosphate
                                                    7693-13-2, Calcium citrate
     9000-01-5, Gum arabic 9000-07-1, Carrageenan 9000-30-0, Guar gum 9000-65-1, Tragacanth 9000-69-5, Pectin 9002-89-5, Polyvinyl alco
     9000-65-1, Tragacanth 9000-69-5, Pectin 9002-89-5, Polyviny 9003-39-8, Povidone 9004-32-4, Sodium carboxymethyl cellulose
                                                  9002-89-5, Polyvinyl alcohol
     9004-53-9, Dextrin 9004-62-0, Hydroxyethyl cellulose 9004-64-2,
     Hydroxypropyl cellulose 9004-65-3, Hydroxypropyl methyl cellulose
     9004-67-5, Methyl cellulose 9005-25-8, Starch, biological studies
     9005-32-7, Alginic acid 9050-36-6, Maltodextrin 10103-46-5, Calcium
```

phosphate 11137-98-7, Magnesium aluminate 14807-96-6, Talc, biological studies 16068-46-5, Potassium phosphate 18694-07-0D, Hexametaphosphoric acid, alkali and alkaline earth metal salts 21645-51-2, Aluminum hydroxide, biological studies 22839-47-0, Aspartame 25322-68-3, Polyethylene oxide 34938-90-4, Calcium maleate 39366-43-3, Aluminum magnesium hydroxide 55589-62-3, Acesulfame-K 56038-13-2, Sucralose 68424-04-4, Polydextrose 106392-12-5, Poloxamer 126040-58-2, Calcium polycarbophil RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (chewable tablets comprising alginic acid, carbonate precursor and calcium salt) 9004-34-6, Cellulose, biological studies ΙT RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (microcryst.; chewable tablets comprising alginic acid, carbonate precursor and calcium salt) L12 ANSWER 7 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN ACCESSION NUMBER: 2003:1001577 CAPLUS <<LOGINID::20080311>> DOCUMENT NUMBER: 140:47520 Chewable oral contraceptive TITLE: INVENTOR(S):

Boissonneault, Roger M.; Devries, Tina M.

PATENT ASSIGNEE(S):

Galen Chemicals Limited, Ire.

SOURCE:

U.S., 9 pp., Cont.-in-part of U.S. Ser. No. 286,908. CODEN: USXXAM DOCUMENT TYPE: Patent English LANGUAGE: FAMILY ACC. NUM. COUNT: 1 PATENT INFORMATION: KIND DATE APPLICATION NO. DATE PATENT NO. ____ _____ US 6667050 B1 20031223 US 2001-879028 20010612 US 1999-286908 A2 19990406 PRIORITY APPLN. INFO.: REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT The present invention relates to a chewable, palatable oral AB contraceptive tablet, comprising an oral contraceptive agent, a chewable carrier suitable for human consumption, and not comprising a ferrocene compound, as well. Drug delivery systems ΙT (tablets; chewable oral contraceptive) ΙT 50-70-4, Sorbitol, biological studies 50-99-7, Dextrose, biological studies 57-48-7, Fructose, biological studies 57-50-1, Sucrose, biological studies 63-42-3, Lactose 69-65-8, Mannitol 87-99-0, Xylitol 471-34-1, Calcium carbonate, biological studies 557-04-0, Magnesium stearate 7757-93-9, Dicalcium phosphate 9003-39-8, Povidone 9005-25-8, Corn starch, biological studies 9050-36-6, Maltodextrin 9063-38-1, Sodium starch glycolate 56038-13-2, Sucralose RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (chewable oral contraceptive) L12 ANSWER 8 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:737151 CAPLUS <<LOGINID::20080311>>

139:250306

1c

DOCUMENT NUMBER:

TITLE: Soft tablets containing high molecular weight

polyethylene oxide

INVENTOR(S): Luber, Joseph; Bunick, Frank J.

PATENT ASSIGNEE(S): McNeil-PPC, Inc., USA

SOURCE: U.S. Pat. Appl. Publ., 7 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2003175336	A1	20030918	US 2002-97000		20020313
US 6753009	В2	20040622			
CA 2421685	A1	20030913	CA 2003-2421685		20030312
PRIORITY APPLN. INFO.:			US 2002-97000	A	20020313
REFERENCE COUNT:	24	THERE ARE 24	CITED REFERENCES	AVAIL	ABLE FOR THIS
		RECORD. ALL	CITATIONS AVAILABL	E IN	THE RE FORMAT

AB . . . oxide (average mol. weight 5,000,000), vitamin E granules 13.3, erythritol 100, crospovidone 25, colorant 2.5, coated ibuprofen 282.1, flavors 15, sucralose 10, dextrose monohydrate 658, and lubricants 7.5 parts.

IT Drug delivery systems

(tablets, chewable; immediate-release matrixes containing high mol. weight PEG and antioxidants for soft tablets)

L12 ANSWER 9 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:833295 CAPLUS <<LOGINID::20080311>>

DOCUMENT NUMBER: 137:329468

TITLE: Over-coated chewing gum formulations

INVENTOR(S): Ream, Ronald L.; Greenberg, Michael J.; Wokas, William

J.; Corriveau, Christine L.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 21 pp., Cont.-in-part of U.S.

6,355,265. CODEN: USXXCO

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 22

PATENT INFORMATION:

PATENT NO.	KIND DATE	APPLICATION NO.	DATE
US 2002159956	A1 20021031	US 2001-990628	20011113
CA 2431856	A1 19980604		19961127
WO 2000035296	A1 20000622	WO 1999-US29742	19991214
W: AE, AL, AM,	AT, AU, AZ, BA,	BB, BG, BR, BY, CA, CH,	CN, CR, CU,
CZ, DE, DK,	DM, EE, ES, FI,	GB, GD, GE, GH, GM, HR,	HU, ID, IL,
IN, IS, JP,	KE, KG, KP, KR,	KZ, LC, LK, LR, LS, LT,	LU, LV, MA,
MD, MG, MK,	MN, MW, MX, NO,	NZ, PL, PT, RO, RU, SD,	SE, SG, SI,
SK, SL, TJ,	TM, TR, TT, TZ,	UA, UG, US, UZ, VN, YU,	ZA, ZW
RW: GH, GM, KE,	LS, MW, SD, SL,	SZ, TZ, UG, ZW, AT, BE,	CH, CY, DE,
DK, ES, FI,	FR, GB, GR, IE,	IT, LU, MC, NL, PT, SE,	BF, BJ, CF,
CG, CI, CM,	GA, GN, GW, ML,	MR, NE, SN, TD, TG	
US 6355265	B1 20020312	US 2000-510878	20000223

```
EP 1347746
                           A1 20031001 EP 2001-953503 20010717
          R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
              IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
     US 2004180007 A1 20040916
                                                 US 2003-743609
                                                                           20031222
     US 7078052
                           В2
                                  20060718
                                                 US 1999-286818 A2 19990406
PRIORITY APPLN. INFO.:
                                                WO 1999-US29742 W 19991214
US 2000-510878 A2 20000223
CA 1996-2271889 A3 19961127
WO 1996-US18977 A2 19961127
US 1998-112389P P 19981215
US 1999-308972 A2 19990527
US 1999-389211 A2 19990902
US 2000-671552 B1 20000927
WO 2001-US22360 W 20010717
     . . . caffeine chewing gum pieces (sticks), which were chewed for 15
AB
     min and removed. The reference treatment was one 100 mg chewable
     No-Doz tablet, which was chewed and swallowed. The caffeine
     chewing gum pieces appear to have a much faster rate of absorption that
     the No-Doz chewable tablets. The areas and peak
     concns. of the chewing gum were less than half that of No-Doz even though
     the gum. . .
     50-99-7, Dextrose, biological studies 56-40-6, Glycine, biological studies 57-48-7, Fructose, biological studies 81-07-2, Saccharin 87-99-0, Xylitol 90-80-2, Glucono-\delta-lactone 90-82-4,
     Pseudoephedrine 103-90-2, Acetaminophen 121-32-4, Ethyl vanillin
     121-33-5, Vanillin 527-07-1, Sodium gluconate 585-88-6, Maltitol
     1405-86-3 4468-02-4, Zinc gluconate 4940-11-8, Ethyl maltol
     9004-10-8, Insulin, biological studies 22839-47-0, Aspartame
     55589-62-3, Acesulfame-k 56038-13-2, Sucralose 64519-82-0,
     Isomalt
     RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
         (over-coated chewing gum formulations with improved drug
         bioavailability)
L12 ANSWER 10 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:674573 CAPLUS <<LOGINID::20080311>>
DOCUMENT NUMBER:
                           137:206554
TITLE:
                           Chewable tablets containing
                          hydrate excipients.
INVENTOR(S):
                          Bunick, Frank J.; Luber, Joseph
PATENT ASSIGNEE(S): McNeil-PPC, Inc., USA
SOURCE:
                          U.S. Pat. Appl. Publ., 5 pp.
                           CODEN: USXXCO
DOCUMENT TYPE:
                          Patent
LANGUAGE:
                           English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:
                     KIND
                                   DATE APPLICATION NO. DATE
     PATENT NO.
                           ____
                                   _____
                                                 ______
     US 2002122822 A1 20020905
US 6814978 B2 20041109
US 2003175339 A1 20030918
                                               US 2000-752601
                                                                           20001229
                                                US 2003-413804 20030415
US 2000-752601 A1 20001229
PRIORITY APPLN. INFO.:
                    18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS
REFERENCE COUNT:
```

```
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT
    Chewable tablets containing hydrate excipients.
ΤI
AΒ
    . . tablet for a sufficient time to decrease the hardness of the
    tablet by at least about 20%. A composition contained sucralose 8.0,
    coated ibuprofen (69.0%) 140.6, flavor 10.0, dextrose
    monohydrate 850.0, Crospovidone 15.0, and Mg stearate 7.5.
ST
    tablet chewable hydrate excipient
    Compression
ΙT
    Hardness (mechanical)
    Particle size
        (chewable tablets containing hydrate excipients)
ΤT
    Drug delivery systems
        (tablets, chewable; chewable
       tablets containing hydrate excipients)
    9003-39-8D, crosslinked
ΤT
    RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL
     (Biological study); USES (Uses)
        (Crospovidone; chewable tablets containing hydrate
       excipients)
    5949-29-1, Citric acid monohydrate 7782-85-6, Phosphoric acid, disodium
    salt, heptahydrate 7789-77-7, Dibasic calcium phosphate dihydrate
    9004-34-6, Cellulose, biological studies 9004-53-9, Dextrin
                                                                   9005-25-8,
    Starch, biological studies 9005-32-7, Alginic acid 9050-36-6,
    Maltodextrin 9063-38-1, Sodium starch glycolate 10028-24-7, Phosphoric
    acid, disodium salt, dihydrate 10039-32-4, Phosphoric acid, disodium
    salt, dodecahydrate 10049-21-5, Monosodium phosphate monohydrate
    13472-35-0, Monosodium phosphate dihydrate 14431-43-7, Dextrose
    monohydrate 64044-51-5, Lactose monohydrate
                                                   74811-65-7, Croscarmellose
    sodium
    RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL
     (Biological study); USES (Uses)
        (chewable tablets containing hydrate excipients)
    58-73-1, Diphenhydramine 90-82-4, Pseudoephedrine
                                                         103-90-2,
ΙT
    Acetaminophen 113-92-8, Chlorpheniramine 125-71-3, Dextromethorphan
    471-34-1, Calcium carbonate, biological studies
                                                    546-93-0, Magnesium
    carbonate
               1309-42-8, Magnesium hydroxide 1309-48-4, Magnesium oxide,
    biological studies
                         15687-27-1, Ibuprofen
                                                21645-51-2, Aluminum
    hydroxide, biological studies
    RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
        (chewable tablets containing hydrate excipients)
L12 ANSWER 11 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:
                        DOCUMENT NUMBER:
                        137:174936
TITLE:
                        Over-coated product including consumable center and
                        medicament
INVENTOR(S):
                        Ream, Ronald L.; Matulewicz, Leonard; Wokas, William
                        J.
PATENT ASSIGNEE(S):
                        USA
                        U.S. Pat. Appl. Publ., 14 pp., Cont.-in-part of U.S.
SOURCE:
                        Ser. No. 631,326.
                        CODEN: USXXCO
DOCUMENT TYPE:
                        Patent
LANGUAGE:
                        English
FAMILY ACC. NUM. COUNT: 22
PATENT INFORMATION:
```

```
      KIND
      DATE
      APPLICATION NO.
      DATE

      ----
      -----
      ------

      A1
      20020815
      US 2002-44113
      20020109

      A1
      19980604
      CA 1996-2431856
      19961127

      PATENT NO. KIND DATE
      _____
      US 2002110581
      CA 2431856
      US 6355265 B1 20020312 US 2000-510878 20000223 EP 1347746 A1 20031001 EP 2001-953503 20010717
          R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
               IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
      US 2004180007 A1 20040916
                                                   US 2003-743609
     US 7078052

US 2006141008

A1 20060629

US 2005-269980

20051109

US 2006121092

A1 20060608

US 2005-273941

20051115

US 2006121093

A1 20060608

US 2005-273942

20051115

US 1999-286818

A2 19990406

US 2000-510878

A2 20000223

US 2000-631326

A2 20000803

CA 1996-2271889

A3 19961127

WO 1999-US29742

A2 19991214

US 2000-671552

B1 20000927
      US 7078052
                             B2 20060718
PRIORITY APPLN. INFO.:
                                                    WO 2001-US22360 W 20010717
US 2002-44113 A2 20020109
     Methods for manufacturing products for delivering a medicament or agent to an
AΒ
      individual are provided. The product, e,g, a tablet or gum,
      comprises a chewable consumable center and a coating containing a
      medicament or agent, a high-intensity sweetener and a taste-masking agent.
      By chewing the. . .
     Drug delivery systems
ΤТ
         (tablets, chewable; chewing compns. based on
         confectionary center and drug coating)
      77-92-9, Citric acid, biological studies 81-07-2, Saccharin 87-99-0,
ΤT
      Xylitol 89-78-1, Menthol 121-33-5, Vanillin 22839-47-0, Aspartame
      55589-62-3, Acesulfame-k 56038-13-2, Sucralose
      RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL
      (Biological study); USES (Uses)
          (chewing compns. based on confectionary center and drug coating)
      50-70-4, Sorbitol, biological studies 50-99-7, Dextrose,
      biological studies 56-81-5, Glycerin, biological studies 90-82-4,
      Pseudoephedrine 103-90-2, Acetaminophen 471-34-1, Calcium carbonate,
      biological studies 9004-10-8, Insulin, biological studies 9050-36-6,
      Maltodextrin 97444-70-7, Talha gum
      RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
          (chewing compns. based on confectionary center and drug coating)
L12 ANSWER 12 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:143205 CAPLUS <<LOGINID::20080311>>
                            136:189384
DOCUMENT NUMBER:
TITLE:
                             Oral delivery of pharmaceuticals via encapsulation
                            Battey, Alyce S.; Battey, Jacob
INVENTOR(S):
                           USA
PATENT ASSIGNEE(S):
                             U.S. Pat. Appl. Publ., 9 pp.
SOURCE:
                             CODEN: USXXCO
DOCUMENT TYPE:
                            Patent
                             English
LANGUAGE:
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:
```

```
APPLICATION NO. DATE
     PATENT NO.
                         KIND DATE
     US 2002022057 A1 20020221 US 2001-931793 20010817 WO 2003009834 A1 20030206 WO 2001-US25791 20010817
         W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
              CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,
              HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,
              LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO,
              RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ,
              VN, YU, ZA, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
              DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
              BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     AU 2001285022 A1 20030217 AU 2001-285022 20010817
                                               US 2000-225877P P 20000817
WO 2001-US25791 W 20010817
PRIORITY APPLN. INFO.:
     . . Benefits of this invention include portability and the ability to
AΒ
     take pharmaceuticals without water and without the off taste of
     chewable tablets, thereby leading to increased patient
     compliance. For example, diphenhydramine, an antihistamine and sedative,
     was encapsulated via spray drying. Diphenhydramine hydrochloride. . .
     50-70-4, Sorbitol, biological studies 50-99-7, Dextrose, biological studies 57-48-7, Fructose, biological studies
ΙT
     Sucrose, biological studies 63-42-3, Lactose 69-65-8, Mannitol
     69-79-4, Maltose 81-07-2, Saccharin 87-99-0, Xylitol 100-88-9, Cyclamate 128-44-9, Saccharin sodium 3844-45-9, FD&C Blue 1
     9050-36-6, Maltodextrin 22839-47-0, Aspartame 55589-62-3, Acesulfame
     potassium 56038-13-2, Sucralose 165450-17-9, Neotame
     RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
        (drug encapsulation for dissoln. in and absorption through oral cavity)
L12 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2001:300547 CAPLUS <<LOGINID::20080311>>
DOCUMENT NUMBER:
                          134:316140
TITLE:
                         Pharmaceutical compositions containing neotame
INVENTOR(S):
                         Ponakala, Subbarao V.
                       The Nutrasweet Company, USA
PATENT ASSIGNEE(S):
                         PCT Int. Appl., 21 pp.
SOURCE:
                          CODEN: PIXXD2
DOCUMENT TYPE:
                          Patent
LANGUAGE:
                          English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:
     PATENT NO. KIND DATE APPLICATION NO. DATE
                      A2 20010426
A3 20080103
     WO 2001028590
                                              WO 2000-US28731
                                                                      20001018
     WO 2001028590
         W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
              SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU,
              ZA, ZW
```

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,

```
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
             CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG, AP, EA, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM, EP, OA
PRIORITY APPLN. INFO.:
                                           US 1999-160305P
                                                              P 19991019
    Drug delivery systems
        (tablets, chewable; pharmaceutical compns. containing
     50-70-4, Sorbitol, biological studies 50-99-7, Dextrose,
ΙT
     biological studies 57-48-7, Fructose, biological studies 57-50-1,
     Sucrose, biological studies 57-50-1D, Sucrose, derivs. 58-86-6, Xylose, biological studies 59-23-4, Galactose, biological studies
     69-65-8, Mannitol 69-79-4, Maltose 81-07-2, Saccharin 87-99-0,
     Xylitol 100-88-9, Cyclamate 100-88-9D, Cyclamate, derivs. 103-90-2,
     Acetaminophen 471-34-1, Calcium carbonate, biological studies
     557-04-0, Magnesium stearate 608-66-2, Galactitol 3458-28-4, Mannose
     5556-48-9, Ribulose 9005-25-8D, Starch, partially hydrolyzed, biological
    studies 9050-36-6, Maltodextrin 20702-77-6, Neohesperidin dihydrochalcone 22839-47-0, Aspartame 27215-73-2 33665-90-6,
     Acesulfame 53956-04-0, Monoammonium glycyrrhizate 56038-13-2,
     Sucralose 64519-82-0, Isomalt 80863-62-3, Alitame
     165450-17-9, Neotame 188627-84-1, Multivitamins 335329-29-8
     RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
        (pharmaceutical compns. containing neotame)
L12 ANSWER 14 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1998:197386 CAPLUS <<LOGINID::20080311>>
DOCUMENT NUMBER:
                        128:275080
TITLE:
                        Directly compressible lactitol granules and tablets
                        Pearson, Julita; Olinger, Philip
INVENTOR(S):
                      Xyrofin Oy, Finland; Pearson, Julita; Olinger, Philip
PATENT ASSIGNEE(S):
SOURCE:
                        PCT Int. Appl., 25 pp.
                        CODEN: PIXXD2
DOCUMENT TYPE:
                        Patent
LANGUAGE:
                        English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:
     PATENT NO.
                   KIND DATE APPLICATION NO. DATE
                       ____
     WO 9811878 A1 19980326 WO 1997-FI548 19970916 <--
        W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
             DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR,
            KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ,
            PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG,
             US, UZ, VN, YU, ZW
         RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR,
             GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA,
             GN, ML, MR, NE, SN, TD, TG
     US 5846568
                         Α
                                19981208
                                            US 1996-715825
                                                                   19960919 <--
     CA 2263495
                         Α1
                                19980326
                                            CA 1997-2263495
                                                                   19970916 <--
     AU 9743042
                                19980414
                                            AU 1997-43042
                                                                   19970916 <--
                         Α
     AU 729040
                         В2
                                20010125
                        A1
     EP 938301
                                19990901
                                           EP 1997-919075
                                                                   19970916 <--
     EP 938301
                        В1
                                20021218
                             20060222
     EP 938301
                         В2
```

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,

```
IE, SI, LT, FI
     JP 2001502667 T 20010227 JP 1998-514321
RU 2187999 C2 20020827 RU 1999-105852
AT 229797 T 20030115 AT 1997-919075
ES 2187769 T3 20030616 ES 1997-919075
KR 2000036234 A 20000626 KR 1999-702316
                                                                              19970916 <--
                                                                             19970916 <--
                                                                             19970916 <--
                                                   ES 1997-919075 19970916

KR 1999-702316 19990318

US 1996-715825 A 19960919

WO 1997-FI548 W 19970916
                                                                              19970916 <--
                                                                              19990318 <--
PRIORITY APPLN. INFO.:
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
                                   RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT
     PATENT NO. KIND DATE APPLICATION NO. DATE
     PΙ
          W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
               DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR,
               KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ,
               PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG,
               US, UZ, VN, YU, ZW
          RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR,
               GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA,
               GN, ML, MR, NE, SN, TD, TG
                                     19981208 US 1996-715825
19980326 CA 1997-2263495
19980414 AU 1997-43042
     US 5846568
CA 2263495
A1 19980326
CA 1997-2263495
AU 9743042
A 19980414
AU 1997-43042
AU 729040
B2 20010125
EP 938301
A1 19990901
EP 1997-919075
EP 938301
B1 20021218
EP 938301
B2 20060222
B3 58 FR, GB, GR, IT, LI, LU, NL
                                  19981208
                                                                               19960919 <--
                                                                              19970916 <--
                                                                              19970916 <--
                                                                              19970916 <--
          R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
              IE, SI, LT, FI
     JP 2001502667 T 20010227 JP 1998-514321
RU 2187999 C2 20020827 RU 1999-105852
AT 229797 T 20030115 AT 1997-919075
ES 2187769 T3 20030616 ES 1997-919075
KR 2000036234 A 20000626 KR 1999-702316
                                                                              19970916 <--
                                                                             19970916 <--
                                                                             19970916 <--
                                                                              19970916 <--
                                                                              19990318 <--
     cellulose qum lactitol tablet granule; lactitol direct
     compression tablet granule
     63-42-3, Lactose 69-65-8, Mannitol 81-07-2, Saccharin 87-99-0,
      Xylitol 100-88-9, Cyclamate 585-86-4, Lactitol 9000-01-5, Gum arabic
      9000-11-7D, salts 9003-39-8, Polyvinylpyrrolidone 9004-32-4
      9004-64-2 9005-25-8D, Starch, hydrolyzates, hydrogenated, biological
      studies 9050-36-6, Maltodextrin 13241-33-3, Neohesperidin
      55589-62-3, Acesulfame K 56038-13-2, Sucralose 57817-89-7,
      Stevioside 81025-03-8, Lactitol dihydrate 81025-04-9, Lactitol
     monohydrate 132339-63-0, Lactitol trihydrate
      RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
         (directly compressible lactitol granules and tablets)
=> log h
                                                          SINCE FILE
COST IN U.S. DOLLARS
                                                               ENTRY
                                                                         SESSION
FULL ESTIMATED COST
                                                              127.71
                                                                         127.92
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE TOTAL ENTRY SESSION
```

CA SUBSCRIBER PRICE

-11.20 -11.20

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 14:14:03 ON 11 MAR 2008